Accretion Pharmaceuticals IPO Allotment Finalised; Listing Scheduled for May 21

May 19, 2025, Mumbai: The allotment status of Accretion Pharmaceuticals’ initial public offering (IPO) is expected to be finalised today, Monday, May 19, 2025. The SME IPO, which opened for subscription on May 14 and closed on May 16, received a strong response from investors, being oversubscribed by approximately 7.6 times.

Investors who applied for the IPO can now check their allotment status through the official websites of the National Stock Exchange (NSE) and Kfin Technologies, the registrar for the issue. Allotment status can be accessed directly via:

• NSE Allotment Link: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids
• Kfintech Allotment Link: https://ipostatus.kfintech.com/

Issue Details and Subscription

Accretion Pharmaceuticals offered 29.46 lakh equity shares through a 100% fresh issue, aggregating to ₹29.75 crore. The price band was set at ₹97–₹101 per share, with investors required to bid in lots of 1,200 shares, amounting to a minimum investment of ₹1,21,200 for retail applicants.

The IPO saw participation from all categories, with shares reserved as follows:

• Retail Investors: 41.51%
• Non-Institutional Investors (NII): 41.51%
• Qualified Institutional Buyers (QIB): 4.81%
• Anchor Investors: 7.17%
• Market Maker: 5.01%

On May 13, 2025, the company raised ₹2.13 crore from anchor investors ahead of the public issue. Jawa Capital Services Pvt. Ltd. acted as the sole book-running lead manager, while Gretex Share Broking Pvt. Ltd. is the market maker for the issue.

Flat Grey Market Premium Indicates Cautious Sentiment

According to market observers, shares of Accretion Pharmaceuticals were trading flat at ₹101 in the grey market today, suggesting a nil grey market premium (GMP). This trend points to a cautious sentiment and hints at a possible flat listing on debut. However, it is important to note that GMP is an informal and unregulated indicator and may not reflect the actual listing performance.

The shares are tentatively scheduled to debut on the NSE SME platform on Wednesday, May 21, 2025.

Utilisation of IPO Proceeds

The company plans to deploy the funds raised from the IPO for several purposes:

• Purchase of new equipment and machinery
• Upgradation of its existing manufacturing facilities
• Repayment/prepayment of certain borrowings
• Funding working capital requirements
• General corporate purposes

Company Overview

Incorporated in 2012 and based in Ahmedabad, Gujarat, Accretion Pharmaceuticals is engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations. Its portfolio includes tablets, capsules, oral liquids, external preparations (such as ointments and medicated shampoos), and oral powders.

The company operates on a B2B model with various marketers and also offers contract manufacturing services. With ISO certifications in quality and environmental management systems, Accretion has extended its global presence to more than 20 countries across Africa, Southeast Asia, and the Middle East.

Post-issue, the promoters’ shareholding will reduce from 100% to 73.48%.

Key Dates 

• Allotment Finalisation: May 19, 2025
• Initiation of Refunds: May 20, 2025
• Credit of Shares to Demat: May 20, 2025
• Listing Date: May 21, 2025

For detailed financial and strategic information, investors are advised to refer to the Red Herring Prospectus (RHP) of Accretion Pharmaceuticals’ IPO.

Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. Please read the offer documents carefully before investing. Investments are subject to market risks and other risks. There is no guarantee of the actual returns that will be given.